trastuzumab duocarmazine + niraparib

Trastuzumab duocarmazine + niraparib is an investigational combination therapy for HER2-expressing locally advanced or metastatic solid tumors, including breast, ovarian, and endometrial cancers. **Trastuzumab duocarmazine** (SYD985) is an antibody-drug conjugate (ADC) consisting of a trastuzumab antibody linked to a synthetic duocarmycin-based cytotoxin via a cleavable linker (valine-citrulline-seco-DUBA). The ADC targets the HER2 receptor and, after internalization, releases the duocarmycin payload to cause DNA damage, resulting in tumor cell death, including a “bystander effect” on neighboring tumor cells[1][5][6]. **Niraparib** (Zejula) is a small molecule oral PARP inhibitor that blocks DNA repair processes, increasing DNA damage and promoting tumor cell death. Combined, these agents aim for synergistic anti-tumor effects through DNA damage and inhibition of repair pathways, potentially improving efficacy and minimizing toxicity by using reduced doses of each agent[1][2][5].

Brand names

Zejula

Other names

trastuzumab duocarmazine + niraparibvic-trastuzumab duocarmazine + niraparib